JP2017526361A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526361A5
JP2017526361A5 JP2017511182A JP2017511182A JP2017526361A5 JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5 JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017511182 A JP2017511182 A JP 2017511182A JP 2017526361 A5 JP2017526361 A5 JP 2017526361A5
Authority
JP
Japan
Prior art keywords
signaling
domain
binding domain
car
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526361A (ja
JP6614619B2 (ja
Filing date
Publication date
Priority claimed from GBGB1415347.2A external-priority patent/GB201415347D0/en
Application filed filed Critical
Publication of JP2017526361A publication Critical patent/JP2017526361A/ja
Publication of JP2017526361A5 publication Critical patent/JP2017526361A5/ja
Application granted granted Critical
Publication of JP6614619B2 publication Critical patent/JP6614619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511182A 2014-08-29 2015-08-28 シグナル伝達系 Active JP6614619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1415347.2A GB201415347D0 (en) 2014-08-29 2014-08-29 Signalling system
GB1415347.2 2014-08-29
PCT/GB2015/052494 WO2016030691A1 (en) 2014-08-29 2015-08-28 Signalling system

Publications (3)

Publication Number Publication Date
JP2017526361A JP2017526361A (ja) 2017-09-14
JP2017526361A5 true JP2017526361A5 (OSRAM) 2018-08-09
JP6614619B2 JP6614619B2 (ja) 2019-12-04

Family

ID=51752358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511182A Active JP6614619B2 (ja) 2014-08-29 2015-08-28 シグナル伝達系

Country Status (18)

Country Link
US (2) US10654927B2 (OSRAM)
EP (2) EP3185875B1 (OSRAM)
JP (1) JP6614619B2 (OSRAM)
KR (1) KR102222615B1 (OSRAM)
CN (1) CN106573989B (OSRAM)
AU (1) AU2015308243B2 (OSRAM)
BR (1) BR112017003906A2 (OSRAM)
CA (1) CA2955668A1 (OSRAM)
CL (1) CL2017000438A1 (OSRAM)
ES (1) ES2910008T3 (OSRAM)
GB (1) GB201415347D0 (OSRAM)
IL (1) IL250101B (OSRAM)
MX (1) MX376613B (OSRAM)
NZ (1) NZ728674A (OSRAM)
RU (1) RU2731638C2 (OSRAM)
SG (1) SG11201700171VA (OSRAM)
WO (1) WO2016030691A1 (OSRAM)
ZA (1) ZA201700466B (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
HRP20201906T1 (hr) 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016176652A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
GB201602563D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) * 2016-02-12 2016-03-30 Autolus Ltd Signalling system
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CN109563507B (zh) * 2016-07-08 2024-03-05 埃克苏马生物技术公司 用于转导淋巴细胞及调节其活性的方法及组合物
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Compositions and methods for t-cell receptors reprogramming using fusion proteins
AU2017357649A1 (en) 2016-11-11 2019-05-23 Autolus Limited Chimeric antigen receptor
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
JP7132249B2 (ja) * 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体(car)を含む細胞
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
CN107475276A (zh) * 2017-09-05 2017-12-15 深圳大学 嵌合抗原受体及其表达基因、四环素调节的嵌合抗原受体修饰的t细胞及其应用
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
US20210113615A1 (en) 2018-04-13 2021-04-22 Ludwig Institute For Cancer Research Ltd. Heterodimeric inactivatable chimeric antigen receptors
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
AU2019269118B2 (en) 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
KR20210073520A (ko) * 2018-09-05 2021-06-21 포세이다 테라퓨틱스, 인크. 동종이계 세포 조성물 및 이의 사용 방법
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor
GB201816839D0 (en) * 2018-10-16 2018-11-28 Glaxosmithkline Ip Dev Ltd Novel control switch
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
GB202104030D0 (en) 2021-03-23 2021-05-05 Autolus Ltd Signalling system
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
LT2956175T (lt) * 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
RS65484B1 (sr) 2013-05-13 2024-05-31 Cellectis Cd19 specifični himerni antigenski receptor i njegove primene
WO2015075468A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US9791929B2 (en) * 2014-10-31 2017-10-17 Elwha Llc Tactile control system
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
NZ743983A (en) * 2016-01-11 2025-08-29 Univ Leland Stanford Junior Chimeric proteins and methods of regulating gene expression
GB201602563D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201602571D0 (en) 2016-02-12 2016-03-30 Autolus Ltd Signalling system
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell

Similar Documents

Publication Publication Date Title
JP2017526361A5 (OSRAM)
Kamiya et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
RU2017105515A (ru) Сигнальная система
JP6909844B2 (ja) 細胞
JP7068459B2 (ja) Nyeso tcr
Zhao et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
Jamieson et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing
Dargel et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice
JP2023518049A (ja) 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
Zhang et al. Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
JP2016538855A5 (OSRAM)
JP2019530431A5 (OSRAM)
RU2016124278A (ru) Клетка
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
KR20240063204A (ko) Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
JP2019535262A5 (OSRAM)
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
JP2016520074A5 (OSRAM)
JP2021503006A5 (OSRAM)
WO2017130223A3 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP2017513478A5 (OSRAM)
JP2019506841A5 (OSRAM)
JP2020512973A5 (OSRAM)
US20230149460A1 (en) Methods for generating engineered memory-like nk cells and compositions thereof